期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Wnt/β-catenin信号通路及与之相关骨质疏松药物研究 被引量：9

Wnt/β-catenin signaling pathway and the research of osteoporosis-associated drugs
暂未订购
导出
摘要 目的 Wnt/β-catenin信号通路在维持骨组织平衡过程中发挥至关重要的作用,主要通过调节信号通路过程中的三类抑制物实现,分别为Sclerostin、Dickkopfs(DKKs)、Secreted frizzled-related proteins(SFRPs)。同时,与之相关的促进骨形成的新药,如Sclerostin单克隆抗体(AMG 785)和DKK1单克隆抗体(RH2-18),正在进行动物及III期临床试验。本文就Wnt/β-catenin信号通路的结构及分布,该通路及其调节机制对骨代谢的作用及与之相关的骨质疏松药物研究作一综述。 Wnt/β-catenin signaling pathway plays an important role in maintaining the balance of bone tissues, which is primarily realized through the regulation of 3 types of inhibitors： sclerostin, dickkopfs （ DKKs ） , and secreted frizzled-related proteins （ SFRPs） .Moreover, the pathway-targeted drugs that promoting the bone formation, such as sclerostin monoclonal antibody （ AMG 785） and DKK1 monoclonal antibody （RH2-18）, are in animal and Phase Ⅲ clinical trials.This article reviews the structure and distribution of Wnt/β-catenin signaling pathway, its function and mechanism in bone metabolism, and the researches of pathway-targeted drugs.
作者 楼超 陈鸿亮 徐华梓
机构地区 温州医科大学附属第二医院骨科
出处 《中国骨质疏松杂志》 CAS CSCD 北大核心 2014年第1期78-83,共6页 Chinese Journal of Osteoporosis
关键词 WNT Β-CATENIN信号通路 骨质疏松 药物 Sclerostin Wnt/β-catenin signaling pathway Sclerostin Osteoporosis Drug
分类号 R68 [医药卫生—骨科学]
  • 相关文献

参考文献58

  • 1NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy: Osteoporosis prevention, diagnosis, and therapy.JAMA ,2001,285(6) :785-795.
  • 2Doggrell SA. Recent important clinical trials of drugs in osteoporosis. Expert Opin Pharmacother ,2004,5 (7) : 1635-1638.
  • 3lohnell 0, KanisJA, Oden A, et a1. Mortality after osteoporotic fractures. Osteoporos Int ,2004, 15 (I) :3842.
  • 4Lie DC, Colamarino SA, Song L, et al. W nt signalling regulates adult hippocampal neurogenesis. Nature, 2005, 437 ( 7063 ) : 1370-1375.
  • 5Rijsewijk F, Schuermann M, Wagenaar E, et a1. The Drosophila homolog of the mouse mammary oncogene int-I is identical to the segment polarity gene wingless. Cell, 1987, 50( 4) :649-657.
  • 6Nusslein-Volhard C and Wieschaus E. Mutations affecting segment number and polarity in Drosophila. Nature, 1980, 287 (5785) : 795 -80 I.
  • 7W uJ and Cohen SM. Repression of Teashirt marks the initiation of wing development. Development ,2002, 129 ( 10) :2411-2418.
  • 8Nusse R, van Ooyen A, Cox D, et al. Mode of proviral activation of a putative mammary oncogene (int-l) on mouse chromosome 15. Nature, 1984,307(5947) :131-136.
  • 9Pandur P, Maurus D, Kuhl M. Increasingly complex: new players enter the Wnt signaling network. BioEssays ,2002 ,24 (10): 881-884.
  • 10Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Bioi, 2004, 20 :781-810.

同被引文献126

  • 1杜潇,程中,李旸,周总光,杨烈,张明鸣.γ分泌酶抑制剂DAPT对胰腺癌细胞生长的影响[J].四川大学学报（医学版）,2013,44(5):699-702. 被引量：4
  • 2朱丹,袁芳,孟坤,宋雅娟.黄酮类化合物的研究进展[J].中华中医药杂志,2007,22(6):387-389. 被引量：108
  • 3蒋明,David Yu,林孝义,等.中华风湿病学[M].北京:华夏出版社,2003:773-774.
  • 4De Souza A, Ali -Shaw T, Reddy S M,et al. Inflammatory arthritis fol- lowing ustekinumab treatment for psoriasis : a report of two cases [ J ]. British Journal of Dermatology,2013,168:210.
  • 5Poddubnyy D, Kay - Geert A, Johanna C, et aL Ustekinurnab for the treatment of patients with active ankylosing spondylitis : results of a 28 - week, prospective, open - label, proof - of - concept study (TOPAS) [J]. Ann Rheum Dis,2014,204:248.
  • 6Raychaudhuri S P, Raychaudhuri S K, Genovese M C. IL- 17 receptor and its functional significance in psoriatic arthritis [ J ]. Molecular and Cellular Biochemistry ,2012,359:419.
  • 7Chiricozzi A,Guttman - Yassky E,Su~trez - Farinas M,et al. Integrative responses to IL - 17 and TNF -α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis[J]. Journal of Investi- gative Dermatology ,2011,131:677.
  • 8Mclnnes I B, Sieper J, Braun J,et al. Efficacy and safety of secukinum- ab, a fully human anti -interleukin -17A monoclonal antibody, in pa- tients with moderate - to - severe psoriatic arthritis : a 24 - week, ran- domised, double - blind, placebo - controlled, phase II proof - of - con- cept trial[J]. Ann Rheum Dis ,2014,73:349.
  • 9Papp K A, Langley R G, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate - to - severe plaque psoriasis : a randomized, double - blind, placebo - controlled phase Ⅱ dose - ran- ging study[ J]. British Journal Dermatology, 2013,168:412.
  • 10Krause C, Korchynskyi O, de Rooij K,et al. Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways [ J ]. Journal of Biological Chemistry ,2010,285 ( 53 ) : 1614.

引证文献9

二级引证文献122

中国骨质疏松杂志
2014年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部